Home  |  Contact

UniProtKB/Swiss-Prot Q9UBP0: Variant p.Leu360Val

Spastin
Gene: SPAST
Variant information

Variant position:  360
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  US
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Valine (V) at position 360 (L360V, p.Leu360Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SPG4; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  360
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  616
The length of the canonical sequence.

Location on the sequence:   KFDDIAGQDLAKQALQEIVI  L PSLRPELFTGLRAPARGLLL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KFDDIAGQDLAKQALQEIVILPSLRPELFTGLRAPARGLLL

Mouse                         KFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLL

Rat                           KFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLL

Pig                           KFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLL

Bovine                        KFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLL

Chicken                       KFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLL

Xenopus laevis                KFADIAGQDLAKQALQEIVILPSIRPELFTGLRAPARGLLL

Xenopus tropicalis            KFADIAGQDLAKQALQEIVILPSIRPELFTGLRAPARGLLL

Zebrafish                     RFDDIAGQDLAKQALQEIVILPALRPELFTGLRAPARGLLL

Caenorhabditis elegans        RMDDVAGCHSAKAALEEAVILPALNPNLFKGLRQPVKGILL

Drosophila                    EWTDIAGQDVAKQALQEMVILPSVRPELFTGLRAPAKGLLL

Slime mold                    KWDDVVGLDKVKQSLMESVILPNLRPDVFTGLRAPPKGLLL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 616 Spastin
Topological domain 78 – 616 Cytoplasmic
Region 228 – 616 Sufficient for microtubule severing
Helix 359 – 363


Literature citations

Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic paraplegia.
McCorquodale D.S. III; Ozomaro U.; Huang J.; Montenegro G.; Kushman A.; Citrigno L.; Price J.; Speziani F.; Pericak-Vance M.A.; Zuchner S.;
Clin. Genet. 79:523-530(2011)
Cited for: VARIANTS SPG4 THR-97; ASP-201; SER-314; VAL-360; ALA-464; GLY-498 AND ILE-550;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.